Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 208

1.

Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA.

Circ Heart Fail. 2013 Mar;6(2):219-26. doi: 10.1161/CIRCHEARTFAILURE.112.000129. Epub 2013 Feb 8.

PMID:
23395934
[PubMed - indexed for MEDLINE]
Free Article
2.

Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials.

Meijers WC, Januzzi JL, deFilippi C, Adourian AS, Shah SJ, van Veldhuisen DJ, de Boer RA.

Am Heart J. 2014 Jun;167(6):853-60.e4. doi: 10.1016/j.ahj.2014.02.011. Epub 2014 Mar 5.

PMID:
24890535
[PubMed - indexed for MEDLINE]
Free Article
3.

Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.

Lok DJ, Lok SI, Bruggink-André de la Porte PW, Badings E, Lipsic E, van Wijngaarden J, de Boer RA, van Veldhuisen DJ, van der Meer P.

Clin Res Cardiol. 2013 Feb;102(2):103-10. doi: 10.1007/s00392-012-0500-y. Epub 2012 Aug 12.

PMID:
22886030
[PubMed - indexed for MEDLINE]
4.

Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.

Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN.

Eur J Heart Fail. 2013 May;15(5):511-8. doi: 10.1093/eurjhf/hfs205. Epub 2013 Jan 4.

PMID:
23291728
[PubMed - indexed for MEDLINE]
5.

Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, Adourian A, Böhm M, van Veldhuisen DJ, Komajda M, Cleland JG, Wikstrand J, McMurray JJ, Aukrust P; CORONA Study Group.

Eur Heart J. 2012 Sep;33(18):2290-6. Epub 2012 Apr 17.

PMID:
22513778
[PubMed - indexed for MEDLINE]
Free Article
6.

Osteoprotegerin predicts progression of chronic heart failure: results from CORONA.

Ueland T, Dahl CP, Kjekshus J, Hulthe J, Böhm M, Mach F, Goudev A, Lindberg M, Wikstrand J, Aukrust P, Gullestad L.

Circ Heart Fail. 2011 Mar;4(2):145-52. doi: 10.1161/CIRCHEARTFAILURE.110.957332. Epub 2011 Jan 7.

PMID:
21216833
[PubMed - indexed for MEDLINE]
Free Article
7.

The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Aukrust P.

Am Heart J. 2012 Dec;164(6):878-83. doi: 10.1016/j.ahj.2012.08.021. Epub 2012 Oct 29.

PMID:
23194488
[PubMed - indexed for MEDLINE]
8.

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.

de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ.

Ann Med. 2011 Feb;43(1):60-8. doi: 10.3109/07853890.2010.538080. Epub 2010 Dec 28.

PMID:
21189092
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.

Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, Shirolkar SC, Donahue M, Kitzman DW, Zannad F, Piña IL, O'Connor CM.

Circ Heart Fail. 2012 Jan;5(1):72-8. doi: 10.1161/CIRCHEARTFAILURE.111.963637. Epub 2011 Oct 20.

PMID:
22016505
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials.

Latini R, Gullestad L, Masson S, Nymo SH, Ueland T, Cuccovillo I, Vårdal M, Bottazzi B, Mantovani A, Lucci D, Masuda N, Sudo Y, Wikstrand J, Tognoni G, Aukrust P, Tavazzi L; Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials.

Eur J Heart Fail. 2012 Sep;14(9):992-9. Epub 2012 Jun 27.

PMID:
22740508
[PubMed - indexed for MEDLINE]
11.

Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.

Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL.

Am J Cardiol. 2011 Aug 1;108(3):385-90. doi: 10.1016/j.amjcard.2011.03.056. Epub 2011 May 19.

PMID:
21600537
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.

Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, Gaggin HK, Bhardwaj A, Januzzi JL.

Eur J Heart Fail. 2013 Oct;15(10):1157-63. doi: 10.1093/eurjhf/hft075. Epub 2013 May 10.

PMID:
23666680
[PubMed - indexed for MEDLINE]
13.

Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial.

Gravning J, Askevold ET, Nymo SH, Ueland T, Wikstrand J, McMurray JJ, Aukrust P, Gullestad L, Kjekshus J; CORONA Study Group.

Circ Heart Fail. 2014 Jan;7(1):96-103. doi: 10.1161/CIRCHEARTFAILURE.113.000450. Epub 2013 Nov 27.

PMID:
24284025
[PubMed - indexed for MEDLINE]
Free Article
14.

Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.

Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ.

Clin Res Cardiol. 2010 May;99(5):323-8. doi: 10.1007/s00392-010-0125-y. Epub 2010 Feb 4.

PMID:
20130888
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION.

Fiuzat M, Schulte PJ, Felker M, Ahmad T, Neely M, Adams KF, Donahue MP, Kraus WE, Piña IL, Whellan DJ, O'Connor CM.

J Card Fail. 2014 Jan;20(1):38-44. doi: 10.1016/j.cardfail.2013.11.011. Epub 2013 Dec 1.

PMID:
24304938
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.

Bayes-Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, Zamora E, Urrutia A, Lupón J.

J Am Coll Cardiol. 2014 Jan 21;63(2):158-66. doi: 10.1016/j.jacc.2013.07.087. Epub 2013 Sep 24.

PMID:
24076531
[PubMed - indexed for MEDLINE]
Free Article
17.

Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure.

Hrynchyshyn N, Jourdain P, Desnos M, Diebold B, Funck F.

Arch Cardiovasc Dis. 2013 Oct;106(10):541-6. doi: 10.1016/j.acvd.2013.06.054. Epub 2013 Oct 3.

PMID:
24090952
[PubMed - indexed for MEDLINE]
Free Article
18.

Usefulness of brain natriuretic peptide level at implant in predicting mortality in patients with advanced but stable heart failure receiving cardiac resynchronization therapy.

El-Saed A, Voigt A, Shalaby A.

Clin Cardiol. 2009 Nov;32(11):E33-8. doi: 10.1002/clc.20490.

PMID:
19816874
[PubMed - indexed for MEDLINE]
19.

Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.

Lopez-Andrès N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, Cleland JG, Zannad F, Lacolley P.

Eur J Heart Fail. 2012 Jan;14(1):74-81. doi: 10.1093/eurjhf/hfr151. Epub 2011 Nov 16.

PMID:
22089058
[PubMed - indexed for MEDLINE]
20.

Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.

Gopal DM, Kommineni M, Ayalon N, Koelbl C, Ayalon R, Biolo A, Dember LM, Downing J, Siwik DA, Liang CS, Colucci WS.

J Am Heart Assoc. 2012 Oct;1(5):e000760. doi: 10.1161/JAHA.112.000760. Epub 2012 Oct 25. Erratum in: J Am Heart Assoc. 2013 Jun;2(3):e000194.

PMID:
23316284
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk